Anavex Life Sciences Corp. (AVXL): Cash & Equivalents
$102.58M
As of 2025-09-30
$118.33M
As of 2026-06-30
-11.7%
3-year compound annual growth
+28.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $102.58M | -22.4% | 2026-08-28, Balance as of period end |
| 2024-09-30 | $132.19M | -12.5% | 2026-08-28, Balance as of period end |
| 2023-09-30 | $151.02M | +1.3% | 2024-12-23, Balance as of period end |
| 2022-09-30 | $149.16M | -1.9% | 2023-11-27, Balance as of period end |
| 2021-09-30 | $152.11M | +420.0% | 2022-11-28, Balance as of period end |
| 2020-09-30 | $29.25M | +31.8% | 2021-11-24, Balance as of period end |
| 2019-09-30 | $22.19M | -3.2% | 2020-12-28, Balance as of period end |
| 2018-09-30 | $22.93M | -16.4% | 2019-12-16, Balance as of period end |
| 2017-09-30 | $27.44M | +198.7% | 2019-01-25, Balance as of period end |
| 2016-09-30 | $9.19M | n/a | 2019-01-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | $102.58M | -22.4% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $89.25M | +158.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| Zura Bio Ltd (ZURA) | 2025-12-31 | $109.41M | -38.0% |
| Quince Therapeutics, Inc. (QNCX) | 2025-12-31 | $5.81M | -6.5% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $10.74M | -2.8% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $50.50M | +12.4% |
| LeonaBio, Inc. (LONA) | 2025-12-31 | $69.28M | +43.0% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $18.30M | -50.5% |
Compare AVXL, SRZN, LCTX, ZURA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗